Crescendo Biologics expands ADC programmes with Innovate UK grant


Award will support development of new therapies to target prostate cancer

Cambridge, UK-based Crescendo Biologics is expanding its antibody drug conjugate (ADC) programme following the receipt of a Biomedical Catalyst Award from the UK’s innovation agency, Innovate UK. The award will enable the company to validate and develop Humabody Drug Conjugates (HDCs), a novel product format based on Crescendo’s Humabody antibody fragment technology which has potential for the treatment of a range of solid tumours.

Crescendo’s HDCs combine the targeting specificity of Humabody VH fragments with highly-potent toxin payloads. They are the smallest antibody fragments (12kD) and as such have the potential for rapid, affinity-driven penetration of solid tumours and fast clearance from systemic circulation. This results in a high tumour-to-blood ratio and reduced systemic toxicity, thereby enhancing therapeutic index.

Sign up for your free email newsletter

The new Humabody programme will involve Crescendo collaborating with 'an established player in the ADC space' on the conjugation of a highly potent toxin to a Humabody fragment targeting prostate cancer.